Showing 1489 results
-
Press release /First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal…
-
Press release /Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease…
-
Press release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Story /Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.
-
Press release /New European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
-
Press release /Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…
-
Story /With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.